AAS Cardiomyopathy & Sudden Cardiac Death
The heart-muscle damage behind bodybuilder deaths
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not applicable (harm documentation)
Reference only. Not medical advice.
What can go wrong
Reduced cardiac function, hypertrophy, accelerated atherosclerosis, arrhythmia, and sudden cardiac death. Stimulant fat-burners, dehydration for shows, and concurrent GH/insulin compound the risk.
This is something to take to a clinician. The Atlas can tell you what is known about aas cardiomyopathy & sudden cardiac death in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The most serious documented harm of long-term anabolic-androgenic steroid (AAS) use is cardiac. Baggish and colleagues (Circulation, 2017) used echocardiography to show that long-term AAS users had reduced left-ventricular systolic function and impaired diastolic function compared with non-using weightlifters, with effects related to cumulative exposure. AAS use is linked to left-ventricular hypertrophy, coronary atherosclerosis (driven by sharply lowered HDL), and arrhythmia, a combination implicated in the sudden cardiac deaths reported in competitive bodybuilders. Some structural changes improve after cessation, but not always fully.
Long-term high-dose androgens remodel the heart, sometimes fatally.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Supraphysiological androgens promote left-ventricular hypertrophy, suppress HDL and raise LDL (accelerating coronary plaque), increase hematocrit and clotting risk, and may have direct pro-arrhythmic and pro-fibrotic myocardial effects. The result is a heart that is hypertrophied, under-perfused, and electrically unstable.
Safety in detail
Long-term anabolic-steroid use is associated with structural heart damage that may be partly irreversible. Anyone using or considering supraphysiological androgens should have cardiac evaluation (echocardiogram, lipids, blood pressure) by a physician.
Replacement is not the same as a cycle
This harm is specific to supraphysiological/anabolic-steroid dosing, not physiological TRT. The TRAVERSE trial found cardiovascular neutrality for physiological replacement in hypogonadal men; the cardiomyopathy described here is a feature of long-term high-dose AAS use.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Echocardiogram
- Lipid panel
- Blood pressure
- Hematocrit
- ECG
What people get wrong
Often saidSteroids only hurt the heart if you already have heart disease
ActuallyBaggish 2017 showed measurable systolic and diastolic dysfunction in otherwise-healthy long-term users, related to how long and how much they used, the damage accrues in healthy hearts.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Key study
- Baggish et al., Circulation 2017
- Findings
- Reduced LV systolic & diastolic function
- Mechanisms
- LVH, low HDL, coronary disease, arrhythmia
- Dose-related
- Tied to cumulative AAS exposure
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about AAS Cardiomyopathy & Sudden Cardiac Death. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Baggish et al.2017
Long-term AAS users showed reduced LV systolic function and diastolic dysfunction vs non-using weightlifters (Circulation)